Modele Ogunniyi, MD
Cardiovascular Disease · Atlanta, GANPI 1972650794
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $8,712 of the $12,273 with a category attached, or 71.0%. Novartis accounts for 71.2% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2024 at $5,710 and has fallen 95.2% since, to $272 in 2025.
Across 17 payments — averaging $721.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$9K
- Pfizer$3K
- Amgen$140
- Astrazeneca UK Limited$135
- AstraZeneca$77
- Johnson & Johnson$62
- plus $87 from 3 others
Across 69 payments — averaging $14,441 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$529K
- Boehringer Ingelheim$206K
- Pfizer$118K
- Boehringer Ingelheim International GmbH$73K
- Boehringer Ingelheim Pharma GmbH & Co.kg$53K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$16K
- plus $627 from 2 others
What the payments were for
- Consulting fees$8,71271%
- Speaking & faculty fees$3,00024%
- Food & beverage$5354%
- Education$260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 3 | $8,737 |
| Pfizer | 4 | $3,034 |
| Amgen | 1 | $140 |
| Astrazeneca UK Limited | 1 | $135 |
| AstraZeneca | 1 | $77 |
| Johnson & Johnson | 4 | $62 |
| Novo Nordisk | 1 | $37 |
| Merck | 1 | $26 |
| Abbott | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,273 in reported general payments places this provider in the 85th percentile of 640 cardiovascular disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 42 | $47,376 |
| FarxigaDapagliflozin Propanediol | 27 | $34,989 |
| EntrestoSacubitril/Valsartan | 27 | $31,073 |
| XareltoRivaroxaban | 20 | $21,320 |
| JardianceEmpagliflozin | 20 | $20,045 |
| Metoprolol Succinate | 87 | $1,680 |
| Nifedipine ErNifedipine | 21 | $985 |
| Rosuvastatin Calcium | 72 | $782 |
| Atorvastatin Calcium | 95 | $629 |
| Ezetimibe | 38 | $528 |
| Torsemide | 26 | $475 |
| Carvedilol | 88 | $464 |
| Hydralazine Hcl | 25 | $394 |
| Spironolactone | 58 | $393 |
| Losartan Potassium | 53 | $370 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $3,034 | $47,37642 claims |
| AstraZenecaFarxiga | $77 | $34,98927 claims |
| NovartisEntresto | $8,737 | $31,07327 claims |
| Johnson & JohnsonXarelto | $62 | $21,32020 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 640 cardiovascular disease providers in Georgia.
Other cardiovascular disease in Atlanta
- Joseph MillerAtlanta$573K
- Utpal PandyaAtlanta$221K
- Randolph MartinAtlanta$177K
- Mani VannanAtlanta$157K
- Victor CorriganAtlanta$114K
- Elizabeth OfiliAtlanta$107K
- Isida BykuAtlanta$78K
- Cindy GrinesAtlanta$75K
- Anekwe OnwuanyiAtlanta$56K
- Melvin EcholsAtlanta$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.